MetaVia Inc. (NASDAQ:MTVA) Stock Short Interest Drops 43.2%

MetaVia Inc. (NASDAQ:MTVA – Get Free Report) was the recipient of a significant decrease in short interest during the month of October. As of October 30th, there was short interest totaling 56,090 shares, a decrease of 43.2% from the October 15th total of 98,690 shares. Based on an average daily trading volume, of 70,460 shares, the short-interest ratio is currently 0.8 days. Approximately 1.1% of the company’s stock are sold short.

MetaVia Stock Performance

MTVA opened at $1.25 on Wednesday. MetaVia has a fifty-two week low of $0.97 and a fifty-two week high of $13.42. The firm has a 50-day moving average of $1.44 and a 200 day moving average of $1.60. The firm has a market cap of $8.43 million, a P/E ratio of -0.39 and a beta of 1.24.

MetaVia (NASDAQ:MTVA – Get Free Report) last announced its quarterly earnings data on Friday, November 13th. The company reported ($0.69) earnings per share for the quarter, beating the consensus estimate of ($0.73) by $0.04. Equities research analysts predict that MetaVia will post -2.79 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on MTVA shares. HC Wainwright restated a “buy” rating on shares of MetaVia in a report on Tuesday. Weiss Ratings reiterated a “sell (e+)” rating on shares of MetaVia in a research note on Monday, October 19th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $20.00.

Check Out Our Latest Stock Report on MetaVia

About MetaVia

(Get Free Report)

MetaVia, Inc. is a clinical-stage biotechnology company focused on developing treatments for cardiometabolic diseases, including obesity, metabolic dysfunction-associated steatohepatitis (MASH) and type 2 diabetes. The company’s pipeline includes DA-1726, an investigational dual GLP-1 and glucagon receptor agonist being studied for obesity, and DA-1241, an investigational GPR119 agonist being developed for MASH and type 2 diabetes. These candidates are experimental and have not been established as approved treatments.

Further Reading

Receive News & Ratings for MetaVia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MetaVia and related companies with MarketBeat.com's FREE daily email newsletter.